---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-23-004930"
form_type: "8-K"
ticker: "MBIO"
cik: "0001680048"
company_name: "MUSTANG BIO, INC."
filed_at: "2023-03-29T23:59:59+00:00"
generated_at: "2026-06-17T10:38:45.329760+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Mustang Bio reports FY2022 net loss $77.5M; MB-106 shows 96% ORR, 75% CR

## Summary
- Cash and equivalents $76.7M at Dec 31, 2022, down from $110.6M year-over-year.
- Net loss $77.5M ($0.75/share) vs $66.4M ($0.76/share) in 2021; R&D expenses rose to $62.5M.
- MB-106 CAR T therapy achieved 96% ORR and 75% CR in hematologic malignancies; FDA Orphan Drug Designation for Waldenstrom macroglobulinemia.
- Completed $75M debt financing with Runway Growth Capital; $30M funded at close, $45M milestone-based.
- Plans to treat first pivotal Phase 2 WM patient in Q1 2024; additional data expected in Q2 and Q4 2023.

## SEC filing metadata
- accession: 0001558370-23-004930
- form_type: 8-K
- ticker: MBIO
- cik: 0001680048
- company_name: MUSTANG BIO, INC.
- filed_at: 2023-03-29T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1680048/000155837023004930/0001558370-23-004930-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1680048/000155837023004930/tmb-20230329x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-23-004930
- JSON: https://secwatch.observer/filing/0001558370-23-004930.json
- Plain text: https://secwatch.observer/filing/0001558370-23-004930.txt

## Key facts
- Earnings Releases
  MUSTANG BIO, INC. reported the full year ended December 31, 2022 results: net income Net loss attributable to common stockholders was $77.5 million, or $0.75 per share, for the year ended December 31, 2022, EPS $0.75 per share.
  - Period: the full year ended December 31, 2022
  - Net income: Net loss attributable to common stockholders was $77.5 million, or $0.75 per share, for the year ended December 31, 2022
  - EPS: $0.75 per share
  - Result: reported results
  source text: Mustang Bio Reports Full-Year 2022 Financial Results and Recent Corporate Highlights
  evidence_url: https://www.sec.gov/Archives/edgar/data/1680048/000155837023004930/0001558370-23-004930-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.